New clinical trial to improve the treatment of cognitive impairment associated with schizophrenia. This trial, led by Boehringer Ingelheim and carried out in several hospital centers, investigates the effectiveness of a drug(*) intended to improve cognitive deterioration.
Schizophrenia is a complex and chronic mental disorder suffered by 0.37% of the Spanish population (4.5% are men and 2.9% are women) (**). It causes serious alterations in the person's thinking, perception of reality and behavior.